Navigation Links
BioMS Medical Announces Second Quarter 2008 Results
Date:8/12/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Aug. 12 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the second quarter ended June 30, 2008. BioMS Medical, in partnership with Eli Lilly and Company (Lilly), is developing MBP8298 (dirucotide), a drug for the treatment of MS undergoing pivotal trials in Canada, Europe and the US.

"The three randomized late-stage clinical trials for MBP8298 (dirucotide) continue to progress very well. We recently announced that MAESTRO-03, our U.S. phase III secondary progressive MS trial, was fully recruited with approximately 510 patients," said Kevin Giese, President and CEO of BioMS Medical. "During the quarter, BioMS was also honored to receive the Gold Leaf Award from BIOTECanada in recognition of our selection as "Company of the Year".

Currently, BioMS is conducting three clinical trials and one open-label follow-on trial for MBP8298 (dirucotide):

(x) MAESTRO-01: A randomized, double-blind pivotal phase II/III trial in Canada and Europe evaluating MBP8298 (dirucotide) for the treatment of secondary progressive MS (SPMS). The study has completed full recruitment of 611 patients at 47 trial sites in 10 countries. Patients are administered either MBP8298 (dirucotide) or placebo every six months for a period of two years. To date, there have been eight positive safety reviews from the Data Safety Monitoring Board (DSMB).

(x) MAESTRO-02: An open-label follow-on study to the MAESTRO-01 pivotal trial. Eligible patients who have successfully completed the blinded, placebo controlled MAESTRO-01 trial may choose to receive MBP8298 (dirucotide) on an un-blinded basis. To date, approximately 95% of patients enrolled in MAESTRO-01 have proceeded to MAESTRO-02.

(x) MAESTRO-03: A U.S. pivotal phase III trial evaluating MBP8298 (dirucotide) for the treatme
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... SRI International has been awarded a new ... Allergy and Infectious Diseases (NIAID), part of the National ... therapies for HIV infection and AIDS. The contract supports ... and the complications and opportunistic infections associated with the ... of HIV. According to the World ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 Three ... be semi-finalists in Livestrong’s Big C Competition. Out of ... are each headed to the semi-final round. In this ... exclusive three-month accelerator program, complete with mentoring from thought-leaders ... , As part of the angelMD commitment to the ...
(Date:7/24/2014)... 2014  Neogen Corporation (Nasdaq: NEOG ) ... potential revenue from new rodenticide research are premature. In ... on July 22, 2014, Neogen,s CEO commented about several ... "It was my intent Tuesday at our ... a new type of rodenticide, but certainly not to ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 1000 balances ... takes input on customers’ weighing needs and expertly narrows ... shortlist of balances, scales or even terminals. , ... and smallest weight (or select readability instead) and define ... few additional selection criteria narrows down the list to ...
Breaking Biology Technology:National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... ... ... , , ... (IGEN: OTCBB) , ...
... ... ... ... ...
... ... ... , ... , , ...
Cached Biology Technology:IGEN Networks engages new auditors and converts debt 2Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 2Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 3Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 4Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 5Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 6Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 7Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 8Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 9Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 10Netsmart Technologies Selected by Douglas Gardens Community Mental Health to Provide Behavioral Health Software Solution 2Netsmart Technologies Selected by Douglas Gardens Community Mental Health to Provide Behavioral Health Software Solution 3Netsmart Technologies Selected by Douglas Gardens Community Mental Health to Provide Behavioral Health Software Solution 4Netsmart Technologies Selected by Douglas Gardens Community Mental Health to Provide Behavioral Health Software Solution 5
(Date:7/25/2014)... (July 24, 2014)The link between autism and disrupted ... puzzle of the disease, and is largely unknown. ... Autism Research Initiative (SFARI), George Washington University (GW) ... offer truly integrative and in-depth answers to these ... , LaMantia, professor of pharmacology and physiology ...
(Date:7/25/2014)... consume the healthcare community and remain priority ... To address the worldwide crisis of obesity ... global leaders in diabetes, epidemiology and public ... and development of diverse intervention programs in ... This book on "Global Health Perspectives in ...
(Date:7/25/2014)... of diffusion tensor tractography (DTT), which is derived ... estimation for three motor tracts, such as the ... pathway became possible. The corticospinal tract is known ... function in the human brain. Several studies have ... transtentorial herniation. In addition, some studies have demonstrated ...
Breaking Biology News(10 mins):GW researcher receives grant to answer the how and why of autism during development 2What constitutes an effective response to the global 'diabesity' tsunami? 2
... of scientists who set out to study sex pheromones in a ... a stage in the worms, life cycle, the long-lived dauer larva. ... on July 23, represent the first time that reproduction and lifespan ... scientists once focused on DNA and proteins as the major players ...
... heart grow fonder, but endurance exercise seems to make it ... of Medicine in St. Louis, older people who did endurance ... much younger hearts. The researchers also showed that by one ... , "We know that the heart deteriorates as people ...
... publication of the first issue of , Energy & ... scientific community. Free for all to read online, ... fuel cells, hydrogen storage, thermochemical biofuel production, sustainable energy, ... submitted work of the highest quality, knowing that they ...
Cached Biology News:Sex and lifespan linked in worms 2Exercise could be the heart's fountain of youth 2Exercise could be the heart's fountain of youth 3
... is the universal bioinformatics software that has ... The unique modular design of BioNumerics allows ... any type of data employed for the ... DNA fingerprints, 2-D protein gels, HPLC, VNTR, ...
... early 80s Biosearch Technologies has been ... tools to accelerate the discovery and ... need dual-labeled FRET probes and primers ... for microarray applications, Biosearch can meet ...
UNIVERSAL SCORECARD DNA, 1 EA. * Category: Reagents/Consumables....
mitochondrial proteins (human heart) for 2-D gel electrophoresis *5 mg/mL*...
Biology Products: